The first real-world study of the FDA-approved nonhormone treatment fezolinetant found the menopausal medication improved hot flashes, depression and anxiety in women, according to industry-sponsored research presented at ENDO 2026, the Endocrine Society's annual meeting in Chicago.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗